For years, a quiet fear has shadowed pregnant women who depend on antidepressants: that in treating their own suffering, they might somehow shape the neurology of the child they carry. A sweeping meta-analysis published in The Lancet Psychiatry, drawing on data from more than 600,000 medicated pregnancies, now offers a measured but meaningful reassurance — the medications themselves are not the cause. What the data reveal instead is the deeper story of inheritance and family circumstance, reminding us that the roots of human development are rarely found in a single variable.
Meta-analysis finds no causal link between pregnancy antidepressants and autism
Cobertura Relacionada
Un acuerdo judicial contra Meta en EE UU sienta precedentes para regulaciones efectivas de redes sociales que protejan a…
El País · Aug 27 Erin Brockovich regresa: de enfrentarse a PG&E a desafiar a Meta y Google por los centros de datos de IALa activista ambiental Erin Brockovich, famosa por su victoria contra PG&E, retoma su lucha contra la opacidad de las gr…
Google News · Aug 27 Meta acuerda límites de uso en redes sociales para menores por 17.000 millonesMeta llega a un acuerdo de 17.000 millones de dólares en EE.UU. que incluye restricciones de tiempo de conexión y limita…
El País · Aug 27 Meta paga 18.000 millones en histórico acuerdo que limitará el uso de redes entre menoresMeta acuerda pagar casi 18.000 millones de dólares a 52 fiscales generales estadounidenses y limitar el uso de sus plata…
Sesgo y Encuadre
No hay datos de análisis detallado para esta lente. Intenta volver a ejecutar las lentes desde el panel de administración.
Impacto Geopolítico
Medical research finding no causal link between pregnancy antidepressants and autism has no geopolitical implications; this is a public health science article.
Lente Económico
Meta-analysis of 600,000+ pregnancies finds no causal link between common antidepressants and autism/ADHD, reducing liability risks for pharmaceutical companies and potentially increasing medication adherence among pregnant women.
Pregnant women with depression/anxiety gain reassurance to continue antidepressant treatment without fear of causing neurodevelopmental disorders in offspring, improving maternal mental health outcomes and reducing treatment discontinuation.
Regulatory bodies may update pregnancy safety labeling for antidepressants, potentially reducing warning labels and litigation risk. Healthcare systems may expand mental health coverage for pregnant women. Reduced need for expensive autism/ADHD diagnostic testing and interventions if preventable causes are eliminated.